Navigation Links
CYT003-QbG10 to treat allergy to be presented at the Congress of,the European Academy of Allergology and Clinical Immunology,(EAACI), June 9-13, 2007

Zurich, June 1, 2007-Cytos Biotechnology AG is delighted to inform you about the upcoming scientific presentations of its novel immunotherapeutic CYT003-QbG10 to treat allergic diseases. Recently, positive clinical results for CYT003-QbG10 were obtained and will be presented in different sessions at the XXVI Congress of the European Academy of Allergology and Clinical Immunology (EAACI), taking place from June 9-13, 2007 in Göteborg, Sweden. The EAACI Congress has developed into one of the most important annual events in the field of Allergy in the world. For more information please visit ww.congrex.com/eaaci2007.

CYT003-QbG10 presentations at EAACI 2007: 1) Oral presentation of Abstract No. 146: Dust mite allergy - new treatment options. Dr. med. Thomas Kündig, Head of Research, Department of Dermatology, University Hospital Zurich, Switzerland will present the CYT003-QbG10 study findings relating to house dust mite allergy on Tuesday, June 12, 2007; Oral Abstract Session 26 - Novel developments in basic allergology; 3.30 - 5.00 pm (CET).

2) Poster presentation of Abstract No. 183: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel allergen-independent immunotherapy in patients suffering from grass pollen allergy. Presentation is on Sunday, June 10, 2007; Poster Discussion Session 1 - Immunotherapy; 10.00 - 12.00 am (CET).

3) Poster presentation of Abstract No. 714: A double-blind, placebo-controlled phase IIa study investigating CYT003-QbG10 as a novel immunotherapy in patients suffering from house dust mite allergy. Presentation is on Sunday, June 10, 2007; Poster Session - Allergen SIT IV; 12.00 -1.30 pm (CET).

Background: CYT003-QbG10 is an immunotherapeutic product in development for the treatment of allergy, asthma and atopic dermatitis. It consists of the Immunodrug™ QbG10 which is comprised of the virus-like particle Qb f illed with a synthetic immunostimulatory DNA sequence called G10. CYT003-QbG10 is designed as a disease-modifying treatment and aims to induce a potent Th1 type immune response in order to suppress an "allergic" Th2 type immune response. An earlier, open-label phase IIa study with CYT003-QbG10 combined with an allergen extract of house dust mites at a standard dose showed excellent long-term efficacy in patients allergic to dust mites. Furthermore, two placebo-controlled phase IIa studies with CYT003-QbG10 delivered positive results in patients suffering from allergic rhinitis due to grass pollen allergy and house dust mite allergy. CYT003-QbG10 is currently being studied in clinical trials for the treatment of allergic rhinitis and atopic dermatitis.

Please feel free to contact us at the address below should you wish to receive further information, address questions, or arrange meetings with Cytos Biotechnology directly.

With best regards,

Claudine Blaser

For more information please contact:

Claudine Blaser, PhD Director Corporate Communications Cytos Biotechnology AG Wagistrasse 25, Postfach CH-8952 Schlieren (Zurich) Tel. +41 44 733 47 20 Fax. +41 44 733 47 18 e-mail: claudine.blaser@cytos.com www.cytos.com


'"/>




Related medicine technology :

1. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
2. Placebo-controlled Phase IIa Study with the Immunotherapeutic CYT003-QbG10 Shows Significant Improvement of Allergy Symptoms in Hay Fever Patients
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
5. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
6. Basilea Reports Positive Re-treatment Results from a Second Phase III Trial of Alitretinoin for Patients with Severe Chronic Hand Eczema
7. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
8. Data to be presented at AAN Meeting -Study results of drug candidate for MS
9. Data supporting three Antisoma programmes presented at AACR
10. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
11. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... , June 24, 2016 ... Markets has announced the addition of the " ... offering. This ... and provides an updated review, including its applications in ... the total market, which includes three main industries: pharmaceutical ...
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... 24, 2016 , ... Dr. Amanda Cheng, an orthodontist ... has extensive experience with all areas of orthodontics, including robotic Suresmile technology, ... , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can be used ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... today at the Clinical Decision Making in Emergency Medicine conference in Ponte Vedra ... authored journal articles published in Emergency Medicine Practice and Pediatric Emergency ...
Breaking Medicine News(10 mins):